Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
Conditions: Neuroendocrine Tumors; Carcinoid Syndrome; Diarrhea Interventions: Drug: Telotristat ethyl; Drug: Peptide Receptor Radionuclide Therapy; Other: Placebo Sponsors: Pashtoon Kasi, MD, MS; TerSera Therapeutics LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials